Abstract
The common mechanism of action of aspirin and the chemically unrelated non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of prostaglandin (PG) production due to interference with the enzymatic activity of cyclooxygenase (COX). These agents have long been used as effective treatments for arthritis. The recognition that the inducible isoform COX-2 was associated with inflammation and arthritis led to the hypothesis that PGs produced by a COX-2-dependent pathway were responsible for the inflammation, pain, and tissue destruction. Since the constitutive COX-1 enzyme was identified as responsible for gastroprotection and inhibition of platelet function, the potential for compounds that were both effective and safer than NSAIDs led to rapid development of agents that specifically inhibit COX-2. These agents have now been tested and approved for use by the US Food and Drug Administration for patients with osteoarthritis and rheumatoid arthritis. They have been shown equally effective to comparitor NSAIDs. More importantly, there is a 3.5-fold reduction in the incidence of endoscopic gastroduodenal ulcerations and early data suggesting a similar reduction in clinically significant perforations, symptomatic ulcers, and bleeds. In patients with arthritis at risk for gastrointestinal complications of NSAIDs, specific inhibitors of COX-2 provide an effective and apparently safer form of anti-inflammatory agent.
Current Pharmaceutical Design
Title: Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Volume: 6 Issue: 17
Author(s): Leslie J. Crofford
Affiliation:
Abstract: The common mechanism of action of aspirin and the chemically unrelated non-steroidal anti-inflammatory drugs (NSAIDs) is the inhibition of prostaglandin (PG) production due to interference with the enzymatic activity of cyclooxygenase (COX). These agents have long been used as effective treatments for arthritis. The recognition that the inducible isoform COX-2 was associated with inflammation and arthritis led to the hypothesis that PGs produced by a COX-2-dependent pathway were responsible for the inflammation, pain, and tissue destruction. Since the constitutive COX-1 enzyme was identified as responsible for gastroprotection and inhibition of platelet function, the potential for compounds that were both effective and safer than NSAIDs led to rapid development of agents that specifically inhibit COX-2. These agents have now been tested and approved for use by the US Food and Drug Administration for patients with osteoarthritis and rheumatoid arthritis. They have been shown equally effective to comparitor NSAIDs. More importantly, there is a 3.5-fold reduction in the incidence of endoscopic gastroduodenal ulcerations and early data suggesting a similar reduction in clinically significant perforations, symptomatic ulcers, and bleeds. In patients with arthritis at risk for gastrointestinal complications of NSAIDs, specific inhibitors of COX-2 provide an effective and apparently safer form of anti-inflammatory agent.
Export Options
About this article
Cite this article as:
Crofford J. Leslie, Clinical Experience with Specific COX-2 Inhibitors in Arthritis, Current Pharmaceutical Design 2000; 6 (17) . https://dx.doi.org/10.2174/1381612003398753
DOI https://dx.doi.org/10.2174/1381612003398753 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemistry and Biology of Anti-Inflammatory Marine Natural Products:Molecules Interfering with Cyclooxygenase, NF-kB and Other Unidentified Targets
Current Medicinal Chemistry Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy The Role of Cartilage Oligomeric Matrix Protein (COMP) in Skeletal Disease
Current Drug Targets Identification of a Linear Epitope Recognized by a Monoclonal Antibody Directed to the Heterogeneous Nucleoriboprotein A2
Protein & Peptide Letters Phosphoinositide 3-Kinase Gamma (PI3Kγ) Inhibitors for the Treatment of Inflammation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery subject Index To Volume 2
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Plasma Potassium Levels in Healthy Prehypertension Subjects and the Role of A High Potassium Drink
Current Hypertension Reviews Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry The Involvement of the Nitric Oxide in the Effects and Expression of Opioid Receptors During Peripheral Inflammation
Current Medicinal Chemistry Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Current Drug Safety Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design The Temporal Relationship between Pain Intensity and Pain Interference and Incident Dementia
Current Alzheimer Research B Cell Depletion with Rituximab in Graves Disease and Associated Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Leflunomide, a Reversible Monoamine Oxidase Inhibitor
Central Nervous System Agents in Medicinal Chemistry